Two-year Outcomes after Transurethral Prostate Resection Post-prostatic Artery Embolization Versus Transurethral Prostate Resection Alone For Giant Benign Prostatic Hyperplasia
Urology Journal,
Vol. 20 No. 05 (2023),
23 October 2023
,
Page 361-368
https://doi.org/10.22037/uj.v20i.7627
Abstract
Purpose: To compare the long-term (two-year) efficacy between transurethral resection of the prostate (TURP)
after prostatic artery embolization (PAE) and TURP only for patients with giant (>100 mL) benign prostatic hyperplasia.
Materials and Methods: We retrospectively analyzed data from 61 and 150 patients with giant benign prostatic
hyperplasia treated with PAE+TURP or TURP alone, respectively, from January 2015 to March 2020. We compared
index changes before and after surgery.
Results: The operative time, intraoperative blood loss, postoperative bladder irrigation time, and catheter retention
time in the PAE+TURP group were lower than those of the TURP group, while the speed of resection of the
lesion and hospitalization costs were more significant (P < 0.05). International prostate symptom score (IPSS),
quality of life (QoL), prostate volume, maximum urinary flow rate, detrusor pressure of maximum urinary flow
rate, prostate-specific antigen, and urodynamic obstruction were better in the PAE+TURP group than the TURP
group at 24 months (P < 0.05). Regarding IPSS and QoL scores at 24 months postoperatively compared with the
preoperative period, the PAE+TURP group was better than the TURP group in terms of the storage period, voiding
period, and QoL (P < 0.05). The distribution of postoperative adverse event severity classes was comparable
between the groups (P = 0.984).
Conclusion: In contrast to TURP alone, PAE + TURP is more expensive but provides better postoperative outcomes;
there is no significant difference in terms of the severity grade distribution of postoperative complications.
- giant benign prostatic hyperplasia, transurethral resection of the prostate, prostatic artery embolization, efficacy
How to Cite
References
Langan RC. Benign Prostatic Hyperplasia. Prim Care. 2019;46:223-32.
Capdevila F, Insausti I, Galbete A, Sanchez-Iriso E, Montesino M. Prostatic Artery Embolization Versus Transurethral Resection of the Prostate: A Post Hoc Cost Analysis of a Randomized Controlled Clinical Trial. Cardiovasc Intervent Radiol. 2021;44:1771-7.
Tang Y, Wang RL, Ruan DD, et al. Retrospective observation of the efficacy and safety of prostatic artery embolization combined with transurethral resection of the prostate and simple transurethral resection of the prostate in the treatment of large (> 100 mL) benign prostatic hyperplasia. Abdom Radiol (NY). 2021;46:5746-57.
Abt D, Müllhaupt G, Hechelhammer L, et al. Prostatic Artery Embolisation Versus Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia: 2-yr Outcomes of a Randomised, Open-label, Single-centre Trial. Eur Urol. 2021;80:34-42.
Lebdai S, Chevrot A, Doizi S, et al. Surgical and interventional management of benign prostatic obstruction: Guidelines from the Committee for Male Voiding Disorders of the French Urology Association. Prog Urol. 2021;31:249-65.
Ayyagari R, Powell T, Staib L, et al. Prostatic Artery Embolization Using 100-300-μm Trisacryl Gelatin Microspheres to Treat Lower Urinary Tract Symptoms Attributable to Benign Prostatic Hyperplasia: A Single-Center Outcomes Analysis with Medium-Term Follow-up. J Vasc Interv Radiol. 2020;31:99-107.
Ekengren J, Hahn RG. Blood loss during transurethral resection of the prostate as measured by the HemoCue photometer. Scand J Urol Nephrol. 1993;27:501-7.
Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205-13.
Chow S, Shao J, Wang H. Sample Size Calculations in Clinical Research (2nd Ed.). Chapman & Hall/CRC Biostatistics Series; 2008. page 61.
Knight GM, Talwar A, Salem R, Mouli S. Systematic Review and Meta-analysis Comparing Prostatic Artery Embolization to Gold-Standard Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia. Cardiovasc Intervent Radiol. 2021;44:183-93.
Theurich AT, Leistritz L, Leucht K, et al. Influence of Prostate Artery Embolization on Different Qualities of Lower Urinary Tract Symptoms Due to Benign Prostatic Obstruction. Eur Urol Focus. 2022;8:1323-30.
Xu XF, Liu GX, Zhu C, et al. α1-Blockers and 5α-Reductase Inhibitors Are the Most Recommended Drugs in Treating Benign Prostatic Hyperplasia: An Evidence-Based Evaluation of Clinical Practice Guidelines. Front Pharmacol. 2020;11:311.
Neymark AI, Karpenko AA, Neymark BA, et al. Superselective prostatic artery embolization in the treatment of large benign prostatic hyperplasia. Urologia. 2021;88:374-81.
Sarier M, Duman I, Kilic S, et al. Comparative Results of Transurethral Incision with Transurethral Resection of The Prostate in Renal Transplant Recipients with Benign Prostate Hyperplasia. Urol J. 2018;15:209-213.
Xu Z, Zhou Z, Mu Y, Cai T, Gao Z, Liu L. An Updated Meta-Analysis of the Efficacy and Safety of Prostatic Artery Embolization vs. Transurethral Resection of the Prostate in the Treatment of Benign Prostatic Hyperplasia. Front Surg. 2021;8:779571.
Reich O, Gratzke C, Bachmann A, et al. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. J Urol. 2008;180:246-9.
Ahyai SA, Lehrich K, Kuntz RM. Holmium laser enucleation versus transurethral resection of the prostate: 3-year follow-up results of a randomized clinical trial. Eur Urol. 2007;52:1456-63.
Gilling P, Barber N, Bidair M, et al. Three-year outcomes after Aquablation therapy compared to TURP: results from a blinded randomized trial. Can J Urol. 2020;27:10072-9.
Bachmann A, Tubaro A, Barber N, et al. A European multicenter randomized noninferiority trial comparing 180 W GreenLight XPS laser vaporization and transurethral resection of the prostate for the treatment of benign prostatic obstruction: 12-month results of the GOLIATH study. J Urol. 2015;193:570-8.
Suskind AM, Walter LC, Zhao S, Finlayson E. Functional Outcomes After Transurethral Resection of the Prostate in Nursing Home Residents. J Am Geriatr Soc. 2017;65:699-703.
Bilhim T, Bagla S, Sapoval M, Carnevale FC, Salem R, Golzarian J. Prostatic Arterial Embolization versus Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia. Radiology. 2015;276:310-1.
Insausti I, Sáez de Ocáriz A, Galbete A, et al. Randomized Comparison of Prostatic Artery Embolization versus Transurethral Resection of the Prostate for Treatment of Benign Prostatic Hyperplasia. J Vasc Interv Radiol. 2020;31:882-90.
Sun F, Crisóstomo V, Báez-Díaz C, Sánchez FM. Prostatic Artery Embolization (PAE) for Symptomatic Benign Prostatic Hyperplasia (BPH): Part 2, Insights into the Technical Rationale. Cardiovasc Intervent Radiol. 2016;39:161-9.
Noor A, Fischman AM. Prostate Artery Embolization as a New Treatment for Benign Prostate Hyperplasia: Contemporary Status in 2016. Curr Urol Rep. 2016;17:51.
Moya C, Cuesta J, Friera A, Gil-Vernet Sedó JM, Valderrama-Canales FJ. Cadaveric and radiologic study of the anatomical variations of the prostatic arteries: A review of the literature and a new classification proposal with application to prostatectomy. Clin Anat. 2017;30:71-80.
Tang Y, Zhang JH, Zhu YB, et al. Effect of superselective prostatic artery embolization on benign prostatic hyperplasia. Abdom Radiol (NY). 2021;46:1726-36.
Sun F, Sun X, Shi Q, Zhai Y. Transurethral procedures in the treatment of benign prostatic hyperplasia: A systematic review and meta-analysis of effectiveness and complications. Medicine (Baltimore). 2018;97(51):e13360.
Reichelt AC, Suarez-Ibarrola R, Herrmann TRW, Miernik A, Schöb DS. Laser procedures in the treatment of BPH: a bibliometric study. World J Urol. 2021;39:2903-11.
Das AK, Teplitsky S, Humphreys MR. Holmium laser enucleation of the prostate (HoLEP): a review and update. Can J Urol. 2019;26(4 Suppl 1):13-19.
- Abstract Viewed: 553 times
- 7627/pdf Downloaded: 369 times